Bluejay Diagnostics

Bluejay Diagnostics Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Acton, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-11-10. Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. The company develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. The company is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.